JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

Search

CorMedix Inc

Cerrado

SectorSanidad

7.49 -0.79

Resumen

Variación precio

24h

Actual

Mínimo

7.41

Máximo

7.6

Métricas clave

By Trading Economics

Ingresos

-95M

14M

Ventas

24M

129M

P/B

Media del Sector

3.833

67.147

BPA

0.16

Margen de beneficios

10.901

Empleados

191

EBITDA

9.2M

66M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+81.64% upside

Dividendos

By Dow Jones

Próximas Ganancias

5 may 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

50M

618M

Apertura anterior

8.28

Cierre anterior

7.49

Noticias sobre sentimiento de mercado

By Acuity

11%

89%

16 / 348 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

CorMedix Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

29 abr 2026, 23:53 UTC

Ganancias

Naver Posts Weaker First-Quarter Earnings

29 abr 2026, 23:41 UTC

Acciones populares

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 abr 2026, 23:55 UTC

Ganancias

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 abr 2026, 23:54 UTC

Ganancias

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 abr 2026, 23:52 UTC

Ganancias

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 abr 2026, 23:51 UTC

Ganancias

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 abr 2026, 23:51 UTC

Charlas de Mercado

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 abr 2026, 23:34 UTC

Charlas de Mercado

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 abr 2026, 23:24 UTC

Ganancias

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 abr 2026, 23:24 UTC

Ganancias

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 abr 2026, 23:24 UTC

Ganancias

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 abr 2026, 23:24 UTC

Ganancias

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 abr 2026, 23:22 UTC

Ganancias

China Longyuan 1Q Net CNY1.70B, Down 14%

29 abr 2026, 23:22 UTC

Ganancias

China Longyuan: Power Generation Down 2.9% as of End-March

29 abr 2026, 23:20 UTC

Ganancias

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 abr 2026, 23:20 UTC

Ganancias

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 abr 2026, 23:19 UTC

Ganancias

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 abr 2026, 23:19 UTC

Ganancias

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 abr 2026, 23:19 UTC

Ganancias

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 abr 2026, 23:19 UTC

Ganancias

China Vanke 1Q Loss Narrows>000002.SZ

29 abr 2026, 23:18 UTC

Ganancias

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 abr 2026, 23:17 UTC

Ganancias

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 abr 2026, 23:15 UTC

Ganancias

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 abr 2026, 23:15 UTC

Ganancias

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 abr 2026, 23:13 UTC

Ganancias

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 abr 2026, 23:12 UTC

Ganancias

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 abr 2026, 23:11 UTC

Ganancias

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 abr 2026, 23:11 UTC

Ganancias

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 abr 2026, 23:04 UTC

Ganancias

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 abr 2026, 23:04 UTC

Ganancias

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Comparación entre iguales

Cambio de precio

CorMedix Inc previsión

Precio Objetivo

By TipRanks

81.64% repunte

Estimación a 12 Meses

Media 13.75 USD  81.64%

Máximo 15 USD

Mínimo 13 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CorMedix Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

5

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

9.2 / N/ASoporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Sentimiento

By Acuity

16 / 348 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CorMedix Inc

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
help-icon Live chat